Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Pfizer CEO Bourla, 'disappointed' by COVID vaccine rhetoric, warns politics could threaten uptake
Azar pushes back on congressional concerns of political interference in COVID-19 vaccine approval
Moderna CEO says coronavirus vaccine won't be ready for FDA till late November: FT
LabCorp receives FDA green light for a new type of COVID-19 test using fewer reagents
Gilead Sciences takes back remdesivir distribution as demand drops
Biopharma roundup: White House objects to FDA vaccine rules; Would Trump be treated with Regeneron or Lilly antibodies?
Healthcare roundup: Healthcare workers should be among the first vaccinated, National Academies says in new report
Perlmutter steps down as Merck R&D lead as early research chief Li steps in
GSK's ex-vaccine, pharma lead jumps ship to run G1 Therapeutics

Featured Story

Pfizer CEO Bourla, 'disappointed' by COVID vaccine rhetoric, warns politics could threaten uptake

By Eric Sagonowsky

Pfizer could be just weeks away from reporting early phase 3 data for its coronavirus vaccine—a remarkable feat amid a global pandemic—but as the company nears its goal, politics is increasingly threatening the process, CEO Albert Bourla warned.

Azar pushes back on congressional concerns of political interference in COVID-19 vaccine approval

By Robert King

HHS Secretary Alex Azar denied there will be political interference to approve a COVID-19 vaccine before it is ready, sparing with House lawmakers over a new report.

Moderna CEO says coronavirus vaccine won't be ready for FDA till late November: FT

By Eric Sagonowsky

In recent weeks, COVID-19 vaccine timelines and expectations have increasingly become clearer. Moderna, a leading player, doesn’t expect to be able to file for an emergency use authorization until late November, its CEO told the Financial Times.

LabCorp receives FDA green light for a new type of COVID-19 test using fewer reagents

By Conor Hale

LabCorp has received a new emergency authorization from the FDA for a COVID-19 test that does not require the use of chemical reagents to free the coronavirus’s RNA from a sample.

Gilead Sciences takes back remdesivir distribution as demand drops

By Angus Liu

Gilead's remdesivir is one of only a few drugs to show benefits in COVID-19. After a somewhat chaotic initial rollout by the U.S. government and a drop in demand since, the company is now taking distribution of the antiviral into its own hands.

Biopharma roundup: White House objects to FDA vaccine rules; Would Trump be treated with Regeneron or Lilly antibodies?

By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner

White House officials are objecting to the FDA's proposed standards for COVID-19 vaccine reviews, the WSJ reports. Regeneron and Eli Lilly wouldn't say whether President Trump might be treated for COVID with their antibody cocktails. And LabCorp now has a diagnostic test that works without extraction reagents.

COVID-19 Tracker

Featured Story

Pfizer CEO Bourla, 'disappointed' by COVID vaccine rhetoric, warns politics could threaten uptake

Top Stories

Azar pushes back on congressional concerns of political interference in COVID-19 vaccine approval

Moderna CEO says coronavirus vaccine won't be ready for FDA till late November: FT

LabCorp receives FDA green light for a new type of COVID-19 test using fewer reagents

Gilead Sciences takes back remdesivir distribution as demand drops

Biopharma roundup: White House objects to FDA vaccine rules; Would Trump be treated with Regeneron or Lilly antibodies?

Healthcare roundup: Healthcare workers should be among the first vaccinated, National Academies says in new report

Perlmutter steps down as Merck R&D lead as early research chief Li steps in

GSK's ex-vaccine, pharma lead jumps ship to run G1 Therapeutics